Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus

verfasst von: Biao Peng, Dan Li, Mingjun Qin, Dongdong Luo, Xun Zhang, Hailin Zhao, Su Hu

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Glioma is characterized by high invasion, migration and proliferation abilities. However, the molecular mechanism that triggers the development and recurrence of this tumor is also elusive. This study aims to investigate the biological function and molecular mechanism of microRNA218 in glioma. Human glioma samples were obtained and employed to investigate the correlation between microRNA218 and glioma pathological grading. Glioma cell viability was detected by the cell-counting kit-8 (CCK-8) cell counting assay. Transwell assay and wound-healing assay were employed to examine the migration and invasion of the glioma cells. The mRNA transcription and protein expression of glioma-associated oncogene homolog 1 (GLI1) were analyzed by quantitative RT-PCR and Western blot analysis, respectively. Southwestern blot assay was utilized to explore the possible interaction site of GLI1 and microRNA218. The results indicated that microRNA218 is significantly down-regulated in glioma samples and negatively correlated with the pathological grading. The cell viability was significantly decreased, and migration and invasion were significantly inhibited in microRNA218 treated cells, compared with un-treated cells. GLI1 was discovered acting as a functional downstream target of microRNA218, by which microRNA218 inhibited glioma cell migration and invasion. Southwestern blot result showed that microRNA218 targeted directly the N terminus of GLI1 molecular, and repressed the GLI1 expression in U87MG cells. In conclusion, microRNA218 could reduce the invasion and migration, and inhibit proliferation of glioma cells by suppressing the expression of GLI1 protein at the interacting with the N terminus.
Literatur
1.
2.
Zurück zum Zitat Tu YY, Gao XC, Li G. MicroRNA-218 inhibits glioma invasion, migration, proliferation and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res. 2013. doi:10.1158/0008-5472.CAN-13-0358. Tu YY, Gao XC, Li G. MicroRNA-218 inhibits glioma invasion, migration, proliferation and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res. 2013. doi:10.​1158/​0008-5472.​CAN-13-0358.
3.
Zurück zum Zitat Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479–89.PubMed Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479–89.PubMed
4.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler QD, Gavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.PubMedCentralPubMedCrossRef Louis DN, Ohgaki H, Wiestler QD, Gavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, et al. Exosome can prevent RNase from degrading microRNA in fece. J Gastrointest Oncol. 2011;2(4):215–22.PubMedCentralPubMed Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, et al. Exosome can prevent RNase from degrading microRNA in fece. J Gastrointest Oncol. 2011;2(4):215–22.PubMedCentralPubMed
6.
Zurück zum Zitat Li YY, Wang Y, Yu L, Sun CY, Cheng DG, Yu SZ, et al. miR-146b-5p inhibits glioma migration and invasion by targeting MMP16. Cancer Lett. 2013;339(2):260–9.PubMedCrossRef Li YY, Wang Y, Yu L, Sun CY, Cheng DG, Yu SZ, et al. miR-146b-5p inhibits glioma migration and invasion by targeting MMP16. Cancer Lett. 2013;339(2):260–9.PubMedCrossRef
7.
Zurück zum Zitat Lu S, Mukkada VA, Mangray S, Cleveland K, Shillingford N, Schorl C, et al. MicroRNA profiling in mucosal biopsies of eosinophilic esophagitis patients pre and post-treatment with steroids with relationship with mRNA targets. PLoS One. 2012;7(7):e40676.PubMedCentralPubMedCrossRef Lu S, Mukkada VA, Mangray S, Cleveland K, Shillingford N, Schorl C, et al. MicroRNA profiling in mucosal biopsies of eosinophilic esophagitis patients pre and post-treatment with steroids with relationship with mRNA targets. PLoS One. 2012;7(7):e40676.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Li QJ, Zhou L, Yang F, Wang GX, Zheng H, Wang DS, et al. MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumor Biol. 2012;33(5):1455–65.CrossRef Li QJ, Zhou L, Yang F, Wang GX, Zheng H, Wang DS, et al. MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumor Biol. 2012;33(5):1455–65.CrossRef
10.
Zurück zum Zitat Sana J, Hajduch M, Michalek J, Vyzula R, Slaby O. MicroRNA and glioblastoma: roles in core signaling pathways and potential clinical implications. J Cell Mol Med. 2011;15(8):1636–44.PubMedCrossRef Sana J, Hajduch M, Michalek J, Vyzula R, Slaby O. MicroRNA and glioblastoma: roles in core signaling pathways and potential clinical implications. J Cell Mol Med. 2011;15(8):1636–44.PubMedCrossRef
11.
Zurück zum Zitat Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011;3(5):279–90.PubMedCentralPubMedCrossRef Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011;3(5):279–90.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNA in glioblastomas permits targeted regulation of a cell death gene. PLoS One. 2011;6(9):e24248.PubMedCentralPubMedCrossRef Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNA in glioblastomas permits targeted regulation of a cell death gene. PLoS One. 2011;6(9):e24248.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, et al. miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-beta. Biochem Biophys Res Commun. 2010;402(1):135–40.PubMedCrossRef Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, et al. miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-beta. Biochem Biophys Res Commun. 2010;402(1):135–40.PubMedCrossRef
15.
Zurück zum Zitat Li CH, To KF, Tong JHM, Xiao ZG, Xia T, Lai PBS, et al. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology. 2013;144(5):1086–97.PubMedCrossRef Li CH, To KF, Tong JHM, Xiao ZG, Xia T, Lai PBS, et al. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology. 2013;144(5):1086–97.PubMedCrossRef
16.
Zurück zum Zitat Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y, et al. MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting Caveolin-2 involved in focal adhesion pathway. J Urol. 2013;190(3):1059–68.PubMedCrossRef Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y, et al. MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting Caveolin-2 involved in focal adhesion pathway. J Urol. 2013;190(3):1059–68.PubMedCrossRef
18.
Zurück zum Zitat Lees CW, Zacharias WJ, Tremelling M, Noble CL, Nimmo ER, Tenesa A, et al. Analysis of germline GLI1 variation implicates hedgehog signaling in the regulation of intestinal inflammatory pathways. PLoS Med. 2008;5(12):e239.PubMedCentralPubMedCrossRef Lees CW, Zacharias WJ, Tremelling M, Noble CL, Nimmo ER, Tenesa A, et al. Analysis of germline GLI1 variation implicates hedgehog signaling in the regulation of intestinal inflammatory pathways. PLoS Med. 2008;5(12):e239.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Zhang Y, Dutta A, Abounader R. The role of microRNAs in glioma initiation and progression. Front Biosci (Landmark Ed). 2012;17(1):700–12.CrossRef Zhang Y, Dutta A, Abounader R. The role of microRNAs in glioma initiation and progression. Front Biosci (Landmark Ed). 2012;17(1):700–12.CrossRef
21.
Zurück zum Zitat Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE, et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol. 2010;20(3):539–50.PubMedCrossRef Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE, et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol. 2010;20(3):539–50.PubMedCrossRef
22.
Zurück zum Zitat Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007;67(6):2456–68.PubMedCrossRef Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007;67(6):2456–68.PubMedCrossRef
23.
Zurück zum Zitat Setty M, Helmy K, Khan AA, Silber J, Arvey A, Neezen F, et al. Inferring transcription and microRNA-mediated regulatory programs in gliomastoma. Mol Syst Biol. 2012;8(1):605.PubMedCentralPubMed Setty M, Helmy K, Khan AA, Silber J, Arvey A, Neezen F, et al. Inferring transcription and microRNA-mediated regulatory programs in gliomastoma. Mol Syst Biol. 2012;8(1):605.PubMedCentralPubMed
24.
Zurück zum Zitat Kasper M, Regl G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signaling. Eur J Cancer. 2006;42(4):437–45.PubMedCrossRef Kasper M, Regl G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signaling. Eur J Cancer. 2006;42(4):437–45.PubMedCrossRef
25.
Zurück zum Zitat Nisson M, Unden AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG, et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci U S A. 2000;97(7):3438–43.CrossRef Nisson M, Unden AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG, et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci U S A. 2000;97(7):3438–43.CrossRef
26.
Zurück zum Zitat Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruizi AA. HEDGEHOG-GLI1 signaling regulates human growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007;17(2):165–72.PubMedCentralPubMedCrossRef Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruizi AA. HEDGEHOG-GLI1 signaling regulates human growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007;17(2):165–72.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Ruizi Altaba A, Mas C, Stecca B. The GLI code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol. 2007;17(9):438–47.CrossRef Ruizi Altaba A, Mas C, Stecca B. The GLI code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol. 2007;17(9):438–47.CrossRef
28.
Zurück zum Zitat Agarwal NK, Qu C, Kunkalla K, Liu Y, Vega F. Transcriptional regulation of serine/threonine protein kinase (AKT) genes by glioma-associated oncogene homolog 1. J Biol Chem. 2013;288(21):15390–401.PubMedCrossRef Agarwal NK, Qu C, Kunkalla K, Liu Y, Vega F. Transcriptional regulation of serine/threonine protein kinase (AKT) genes by glioma-associated oncogene homolog 1. J Biol Chem. 2013;288(21):15390–401.PubMedCrossRef
29.
Zurück zum Zitat Shimakawa T, Tostar U, Lauth M, Palaniswamy R, Kasper M, Toftgard R, et al. Novel human Glioma-associated oncogene 1 (GLI1) splice variants reveal distinct mechanism in the terminal teransduction of the hedgehog signal. J Biol Chem. 2008;283(21):14345–54.CrossRef Shimakawa T, Tostar U, Lauth M, Palaniswamy R, Kasper M, Toftgard R, et al. Novel human Glioma-associated oncogene 1 (GLI1) splice variants reveal distinct mechanism in the terminal teransduction of the hedgehog signal. J Biol Chem. 2008;283(21):14345–54.CrossRef
Metadaten
Titel
MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus
verfasst von
Biao Peng
Dan Li
Mingjun Qin
Dongdong Luo
Xun Zhang
Hailin Zhao
Su Hu
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1507-3

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.